• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病:慢性肾脏病的一个新的驱动因素。

Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.

机构信息

Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale Stefani 1, 37126 Verona, Italy.

Nutrition and Metabolism, Faculty of Medicine, University of Southampton.

出版信息

Nat Rev Nephrol. 2017 May;13(5):297-310. doi: 10.1038/nrneph.2017.16. Epub 2017 Feb 20.

DOI:10.1038/nrneph.2017.16
PMID:28218263
Abstract

Non-alcoholic fatty liver disease (NAFLD) is caused by an accumulation of fat in the liver; the condition can progress over time to increase the risk of developing cirrhosis, end-stage liver disease and hepatocellular carcinoma. The prevalence of NAFLD is increasing rapidly owing to the global epidemics of obesity and type 2 diabetes mellitus (T2DM), and NAFLD has been predicted to become the most important indication for liver transplantation over the next decade. It is now increasingly clear that NAFLD not only affects the liver but can also increase the risk of developing extra-hepatic diseases, including T2DM, cardiovascular disease and chronic kidney disease (CKD), which have a considerable impact on health-care resources. Accumulating evidence indicates that NAFLD exacerbates insulin resistance, predisposes to atherogenic dyslipidaemia and releases a variety of proinflammatory factors, prothrombotic factors and profibrogenic molecules that can promote vascular and renal damage. Furthermore, communication or 'crosstalk' between affected organs or tissues in these diseases has the potential to further harm function and worsen patient outcomes, and increasing amounts of evidence point to a strong association between NAFLD and CKD. Whether a causal relationship between NAFLD and CKD exists remains to be definitively established.

摘要

非酒精性脂肪性肝病(NAFLD)是由肝脏脂肪堆积引起的;随着时间的推移,这种情况会增加发展为肝硬化、终末期肝病和肝细胞癌的风险。由于肥胖和 2 型糖尿病(T2DM)在全球的流行,NAFLD 的患病率迅速上升,预计在未来十年内,NAFLD 将成为肝移植的最重要指征。现在越来越清楚的是,NAFLD 不仅影响肝脏,还会增加发生肝外疾病的风险,包括 2 型糖尿病、心血管疾病和慢性肾脏病(CKD),这对医疗保健资源有相当大的影响。越来越多的证据表明,NAFLD 会加重胰岛素抵抗,导致动脉粥样硬化性血脂异常,并释放多种促炎、促血栓形成和促纤维化分子,从而促进血管和肾脏损伤。此外,这些疾病中受影响的器官或组织之间的通讯或“串扰”有可能进一步损害功能并恶化患者预后,越来越多的证据表明,NAFLD 与 CKD 之间存在很强的关联。NAFLD 和 CKD 之间是否存在因果关系仍有待最终确定。

相似文献

1
Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.非酒精性脂肪性肝病:慢性肾脏病的一个新的驱动因素。
Nat Rev Nephrol. 2017 May;13(5):297-310. doi: 10.1038/nrneph.2017.16. Epub 2017 Feb 20.
2
Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.肝外疾病与非酒精性脂肪性肝病:非酒精性脂肪性肝病、2型糖尿病和肠道菌群失调之间的三角关系
Dig Dis. 2016;34 Suppl 1:11-8. doi: 10.1159/000447276. Epub 2016 Aug 22.
3
NAFLD: a multisystem disease.非酒精性脂肪性肝病:一种多系统疾病。
J Hepatol. 2015 Apr;62(1 Suppl):S47-64. doi: 10.1016/j.jhep.2014.12.012.
4
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.非酒精性脂肪性肝病及其与心血管病和其他肝外疾病的关系。
Gut. 2017 Jun;66(6):1138-1153. doi: 10.1136/gutjnl-2017-313884. Epub 2017 Mar 17.
5
Nonalcoholic fatty liver disease - A multisystem disease?非酒精性脂肪性肝病——一种多系统疾病?
World J Gastroenterol. 2016 Nov 21;22(43):9488-9505. doi: 10.3748/wjg.v22.i43.9488.
6
A brief review on the rising incidence of chronic kidney diseases and non-alcoholic fatty liver disease.慢性肾脏病和非酒精性脂肪性肝病发病率上升的简要综述。
Physiol Int. 2019 Dec 1;106(4):305-310.
7
CKD and nonalcoholic fatty liver disease.慢性肾脏病与非酒精性脂肪性肝病。
Am J Kidney Dis. 2014 Oct;64(4):638-52. doi: 10.1053/j.ajkd.2014.05.019. Epub 2014 Jul 30.
8
Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities.非酒精性脂肪性肝病合并慢性肾脏病患者死亡率增加可由代谢性合并症解释。
Clin Res Hepatol Gastroenterol. 2019 Oct;43(5):542-550. doi: 10.1016/j.clinre.2019.02.004. Epub 2019 Mar 1.
9
MAFLD and CKD: An Updated Narrative Review.MAFLD 和 CKD:更新的叙述性综述。
Int J Mol Sci. 2022 Jun 23;23(13):7007. doi: 10.3390/ijms23137007.
10
Complications, morbidity and mortality of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的并发症、发病率和死亡率。
Metabolism. 2020 Oct;111S:154170. doi: 10.1016/j.metabol.2020.154170. Epub 2020 Jan 30.

引用本文的文献

1
The role of the gut microbiota and its metabolites: a new predictor in diabetes and its complications.肠道微生物群及其代谢产物的作用:糖尿病及其并发症的新预测指标。
Eur J Med Res. 2025 Jul 9;30(1):601. doi: 10.1186/s40001-025-02824-9.
2
Multi-omics analysis reveals the efficacy of two probiotic strains in managing feline chronic kidney disease through gut microbiome and host metabolome.多组学分析揭示了两种益生菌菌株通过肠道微生物群和宿主代谢组来管理猫慢性肾病的功效。
Front Vet Sci. 2025 Jun 18;12:1590388. doi: 10.3389/fvets.2025.1590388. eCollection 2025.
3
Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges.
儿童重大疾病中的肝肾相互作用:解析复杂性与临床挑战
J Clin Med. 2025 Jun 2;14(11):3911. doi: 10.3390/jcm14113911.
4
Nephrological, Pulmonary, and Dermatological Complications in the Context of MAFLD/NAFLD: A Narrative Review.MAFLD/NAFLD背景下的肾脏、肺部和皮肤并发症:一项叙述性综述
Metabolites. 2025 Apr 14;15(4):272. doi: 10.3390/metabo15040272.
5
From Liver to Kidney: The Overlooked Burden of Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease.从肝脏到肾脏:慢性肾脏病中非酒精性脂肪性肝病被忽视的负担
J Clin Med. 2025 Apr 5;14(7):2486. doi: 10.3390/jcm14072486.
6
Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.与胰高血糖素样肽-1受体激动剂相关的代谢功能障碍相关脂肪性肝病(MASLD)的胃肠道不良事件:一项系统评价和荟萃分析。
Front Med (Lausanne). 2025 Feb 20;12:1509947. doi: 10.3389/fmed.2025.1509947. eCollection 2025.
7
Metabolic dysfunction-associated fatty liver disease increases risk of chronic kidney disease: a systematic review and meta-analysis.代谢功能障碍相关脂肪性肝病增加慢性肾脏病风险:一项系统评价和荟萃分析
eGastroenterology. 2023 Aug 7;1(1):e100005. doi: 10.1136/egastro-2023-100005. eCollection 2023 Jun.
8
Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis.补充鱼油对代谢功能障碍相关脂肪性肝病的疗效:一项荟萃分析。
Front Nutr. 2025 Jan 24;12:1524830. doi: 10.3389/fnut.2025.1524830. eCollection 2025.
9
Curvilinear association between Framingham Steatosis Index and chronic kidney disease: a nationwide cross-sectional study.弗雷明汉脂肪肝指数与慢性肾脏病之间的曲线关联:一项全国性横断面研究。
Front Med (Lausanne). 2025 Jan 14;11:1518202. doi: 10.3389/fmed.2024.1518202. eCollection 2024.
10
Oxidative stress and inflammation in hemodialysis: a comparison of patients with or without advanced nonalcoholic fatty liver disease (NAFLD).血液透析中的氧化应激与炎症:有无晚期非酒精性脂肪性肝病(NAFLD)患者的比较
Ren Fail. 2025 Dec;47(1):2455523. doi: 10.1080/0886022X.2025.2455523. Epub 2025 Jan 22.